Mediclin (MED.DE) Stock Price

Mediclin Price

XETRA·CLOSED
4.30EUR+0.08 (+1.88 %)
Market closed

Revenue has compounded at 3.9% per year over the past 19 years to 784.49 M EUR. Earnings per share have grown at 6.0% per year over the last 16 years. Mediclin's net margin stands at 3.2%, up from 0.2% several years earlier. Mediclin currently offers a dividend yield of about 0.93%. The payout ratio is around 7% of earnings. Analysts set a median price target of 5.87 EUR, implying 36.4% above the current price. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus. The stock trades about 49% above its 52-week low.

Mediclin stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Mediclin over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Mediclin stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Mediclin's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Mediclin Stock Price History
DateMediclin Price
8/7/20264.30 EUR
8/6/20264.22 EUR
8/5/20264.32 EUR
8/4/20264.30 EUR
7/31/20264.12 EUR
7/30/20264.20 EUR
7/29/20264.14 EUR
7/28/20264.04 EUR
7/27/20264.16 EUR
7/24/20264.26 EUR
7/23/20264.10 EUR
7/22/20264.10 EUR
7/21/20264.16 EUR
7/20/20264.14 EUR
7/17/20264.16 EUR
7/16/20264.16 EUR
7/15/20264.12 EUR
7/14/20264.10 EUR
7/13/20264.10 EUR
7/10/20264.04 EUR
7/9/20264.04 EUR
7/8/20264.08 EUR
7/7/20264.02 EUR
7/6/20264.06 EUR
7/3/20264.00 EUR
7/2/20263.96 EUR
7/1/20263.98 EUR
6/30/20263.96 EUR
6/29/20263.96 EUR
6/26/20263.96 EUR
6/25/20264.00 EUR
6/24/20263.96 EUR
6/23/20263.98 EUR
6/22/20264.00 EUR
6/19/20264.06 EUR
6/18/20264.06 EUR
6/17/20264.04 EUR
6/16/20264.08 EUR
6/15/20264.12 EUR
6/12/20264.06 EUR
6/11/20263.98 EUR
6/10/20264.00 EUR
6/9/20264.20 EUR
6/8/20264.20 EUR
6/5/20264.20 EUR
6/4/20264.20 EUR
6/3/20264.16 EUR
6/2/20264.18 EUR
6/1/20263.94 EUR
5/29/20263.74 EUR
5/28/20263.78 EUR
5/27/20263.76 EUR
5/26/20263.70 EUR
5/25/20263.66 EUR
5/22/20263.60 EUR
5/21/20263.58 EUR
5/20/20263.56 EUR
5/19/20263.58 EUR
5/18/20263.52 EUR
5/15/20263.56 EUR
5/14/20263.60 EUR
5/13/20263.58 EUR
5/12/20263.58 EUR
5/11/20263.58 EUR
5/8/20263.54 EUR
5/7/20263.54 EUR
5/6/20263.60 EUR
5/5/20263.58 EUR
5/4/20263.54 EUR
4/30/20263.38 EUR
4/29/20263.42 EUR
4/28/20263.44 EUR
4/27/20263.48 EUR
4/24/20263.40 EUR
4/23/20263.46 EUR
4/22/20263.40 EUR
4/21/20263.36 EUR
4/20/20263.42 EUR
4/17/20263.44 EUR
4/16/20263.44 EUR
4/15/20263.44 EUR
4/14/20263.32 EUR
4/13/20263.50 EUR
4/10/20263.54 EUR
4/9/20263.44 EUR
4/8/20263.54 EUR
4/7/20263.60 EUR
4/2/20263.40 EUR
4/1/20263.40 EUR
3/27/20263.54 EUR
3/26/20263.44 EUR
3/25/20263.56 EUR
3/24/20263.48 EUR
3/23/20263.78 EUR
3/20/20263.48 EUR
3/19/20263.42 EUR
3/17/20263.60 EUR
3/16/20263.45 EUR
3/13/20263.64 EUR
3/12/20263.55 EUR
3/11/20263.68 EUR
3/10/20263.66 EUR
3/9/20263.56 EUR
3/6/20263.70 EUR
3/5/20263.66 EUR
2/26/20263.88 EUR
2/25/20263.86 EUR
2/24/20263.88 EUR
2/23/20263.84 EUR
2/20/20263.80 EUR
2/19/20263.78 EUR
2/18/20263.82 EUR
2/17/20263.72 EUR
2/16/20263.70 EUR
2/13/20263.52 EUR
2/12/20263.88 EUR
2/11/20263.88 EUR
2/10/20263.88 EUR
2/9/20263.90 EUR
2/6/20263.88 EUR
2/5/20263.90 EUR
2/4/20263.90 EUR
2/3/20263.90 EUR
2/2/20263.90 EUR
1/30/20263.90 EUR
1/29/20263.90 EUR
1/28/20264.02 EUR
1/27/20264.04 EUR
1/26/20263.92 EUR
1/23/20264.06 EUR
1/22/20263.86 EUR
1/21/20263.84 EUR
1/20/20263.96 EUR
1/19/20263.82 EUR
1/16/20264.02 EUR
1/15/20263.84 EUR
1/14/20263.82 EUR
1/13/20263.72 EUR
1/12/20263.72 EUR
1/9/20263.68 EUR
1/8/20263.62 EUR
1/7/20263.70 EUR
1/6/20263.62 EUR
1/5/20263.60 EUR
1/2/20263.60 EUR
12/30/20253.56 EUR
12/29/20253.62 EUR
12/23/20253.56 EUR
12/22/20253.62 EUR
12/19/20253.62 EUR
12/18/20253.60 EUR
12/17/20253.78 EUR
12/16/20253.72 EUR
12/15/20253.80 EUR
12/12/20253.82 EUR
12/11/20253.76 EUR
12/10/20253.78 EUR
12/9/20253.80 EUR
12/8/20253.74 EUR
12/5/20253.80 EUR
12/4/20253.68 EUR
12/3/20253.58 EUR
12/2/20253.36 EUR
12/1/20253.36 EUR
11/28/20253.44 EUR
11/27/20253.38 EUR
11/26/20253.42 EUR
11/25/20253.36 EUR
11/24/20253.44 EUR
11/21/20253.38 EUR
11/20/20253.42 EUR
11/19/20253.50 EUR
11/18/20253.52 EUR
11/17/20253.50 EUR
11/14/20253.46 EUR
11/13/20253.48 EUR
11/12/20253.52 EUR
11/11/20253.42 EUR
11/10/20253.32 EUR
11/7/20253.56 EUR
11/6/20253.62 EUR
11/5/20253.64 EUR
11/4/20253.68 EUR
11/3/20253.74 EUR
10/31/20253.54 EUR
10/30/20253.70 EUR
10/29/20253.50 EUR
10/28/20253.68 EUR
10/27/20253.60 EUR
10/24/20253.64 EUR
10/23/20253.54 EUR
10/22/20253.44 EUR
10/21/20253.44 EUR
10/20/20253.52 EUR
10/17/20253.38 EUR
10/16/20253.40 EUR
10/15/20253.40 EUR
10/14/20253.30 EUR
10/13/20253.28 EUR
10/10/20253.26 EUR
10/9/20253.20 EUR
10/8/20253.20 EUR
10/7/20253.20 EUR
10/6/20253.10 EUR
10/3/20253.22 EUR
10/2/20253.22 EUR
10/1/20253.10 EUR
9/30/20253.14 EUR
9/29/20253.08 EUR
9/26/20252.98 EUR
9/25/20252.98 EUR
9/24/20252.96 EUR
9/23/20252.92 EUR
9/22/20253.04 EUR
9/19/20252.98 EUR
9/18/20252.94 EUR
9/17/20252.96 EUR
9/16/20252.90 EUR
9/15/20252.94 EUR
9/12/20252.92 EUR
9/11/20252.98 EUR
9/10/20253.00 EUR
9/9/20252.98 EUR
9/8/20253.00 EUR
9/5/20252.98 EUR
9/4/20252.88 EUR
9/3/20253.00 EUR
9/2/20253.00 EUR
9/1/20253.10 EUR
8/29/20253.08 EUR
8/28/20253.10 EUR
8/27/20253.00 EUR
8/26/20253.04 EUR
8/25/20253.06 EUR
8/22/20253.06 EUR
8/21/20253.12 EUR
8/20/20252.98 EUR
8/19/20253.04 EUR
8/18/20253.02 EUR
8/15/20253.00 EUR
8/14/20253.18 EUR
8/13/20252.96 EUR
8/12/20253.00 EUR
8/11/20252.98 EUR
Access this data via the Eulerpool API
Get Free API Key

Mediclin Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
730.10 M EUR
12.72 M EUR
-10.78 M EUR
Jan 1, 2024
748.80 M EUR
53.49 M EUR
24.84 M EUR
Jan 1, 2025
784.49 M EUR
38.44 M EUR
25.49 M EUR
Jan 1, 2026 (e)
805.60 M EUR
81.81 M EUR
37.09 M EUR
Jan 1, 2027 (e)
825.83 M EUR
83.86 M EUR
39.69 M EUR
Jan 1, 2028 (e)
846.59 M EUR
85.97 M EUR
43.04 M EUR
Jan 1, 2029 (e)
900.10 M EUR
91.41 M EUR
49.51 M EUR
Jan 1, 2030 (e)
927.10 M EUR
94.15 M EUR
52.98 M EUR

Mediclin Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 10, 2026, 4:36 PM
 
REVENUEM EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM EUR
EBITM EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
DIV.EUR
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
555.00580.00609.00645.00673.00659.00673.00704.00730.00748.00784.00805.00825.00846.00900.00927.00
3.164.505.005.914.34-2.082.124.613.692.474.812.682.482.556.383.00
81.4481.2181.4481.4082.0283.0081.8781.1181.3783.2914.4114.4114.4114.4114.4114.41
452.00471.00496.00525.00552.00547.00551.00571.00594.00623.00113.00116.03118.91121.94129.72133.61
23.0024.006.0015.0022.00–11.0029.0012.0053.0038.0081.0083.0085.0091.0094.00
4.144.140.992.333.27–1.634.121.647.094.8510.0610.0610.0510.1110.14
16.0016.003.007.009.00-8.001.009.00-10.0024.0025.0037.0039.0043.0049.0052.00
100.00–-81.25133.3328.57-188.89-112.50800.00-211.11-340.004.1748.005.4110.2613.956.12
–––0.050.05–––––0.040.040.040.04––
49.1749.1749.1749.1749.1749.1748.1547.5047.5047.5047.5047.5047.5047.5047.5047.50
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Mediclin generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Mediclin retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Mediclin's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Mediclin has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Mediclin's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Mediclin stock margins

The Mediclin margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Mediclin. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Mediclin.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
81.86 %
1.75 %
0.22 %
Jan 1, 2022
81.16 %
4.15 %
1.34 %
Jan 1, 2023
81.44 %
1.74 %
-1.48 %
Jan 1, 2024
83.20 %
7.14 %
3.32 %
Jan 1, 2025
14.51 %
4.90 %
3.25 %
Jan 1, 2026 (e)
14.51 %
10.16 %
4.60 %
Jan 1, 2027 (e)
14.51 %
10.16 %
4.81 %
Jan 1, 2028 (e)
14.51 %
10.16 %
5.08 %

Mediclin Stock Revenue, EBIT, Earnings per Share

The Mediclin earnings per share therefore indicates how much revenue Mediclin has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
13.98 EUR
0.24 EUR
0.03 EUR
Jan 1, 2022
14.84 EUR
0.62 EUR
0.20 EUR
Jan 1, 2023
15.37 EUR
0.27 EUR
-0.23 EUR
Jan 1, 2024
15.76 EUR
1.13 EUR
0.52 EUR
Jan 1, 2025
16.52 EUR
0.81 EUR
0.54 EUR
Jan 1, 2026 (e)
16.96 EUR
1.72 EUR
0.78 EUR
Jan 1, 2027 (e)
17.39 EUR
1.77 EUR
0.84 EUR
Jan 1, 2028 (e)
17.82 EUR
1.81 EUR
0.91 EUR

Mediclin business model & stock analysis

Mediclin AG is a German company specializing in the care and treatment of patients. It was founded in 1984 in Berlin and has since relocated its headquarters to Offenburg. Mediclin operates over 50 healthcare facilities throughout Germany, including hospitals, rehabilitation centers, nursing facilities, and medical care centers. The company employs approximately 10,000 employees and generated a revenue of 1.17 billion euros in 2020.

Mediclin SWOT Analysis

Strengths

Mediclin AG has a strong reputation in the healthcare industry due to its high-quality medical services and state-of-the-art facilities.

The company has a large network of hospitals and clinics, allowing it to serve a wide range of patients and offer diverse medical specialties.

Weaknesses

One weakness of Mediclin AG is its dependency on government contracts and reimbursements, which can be subject to changes in healthcare policies and regulations.

The company may face challenges in maintaining consistent revenue growth as healthcare costs continue to rise and potential budget constraints arise.

Opportunities

There is a growing demand for healthcare services, particularly in specialized areas such as geriatrics and mental health, which presents opportunities for Mediclin AG to expand its offerings.

The company can also explore partnerships and collaborations with research institutions or technology companies to enhance its medical technologies and treatments.

Threats

Increased competition within the healthcare industry poses a threat to Mediclin AG's market share and profitability.

Changes in healthcare regulations and policies, as well as potential economic downturns, can also pose threats to the company's financial stability.

Mediclin Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Mediclin historical P/E ratio, EBIT multiple, and P/S ratio

Mediclin annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Mediclin shares outstanding

The number of shares of Mediclin was 47.5 M in 2025. This indicates how many shares Mediclin is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
48.15 M Stocks
Jan 1, 2022
47.50 M Stocks
Jan 1, 2023
47.50 M Stocks
Jan 1, 2024
47.50 M Stocks
Jan 1, 2025
47.50 M Stocks
Jan 1, 2026 (e)
47.50 M Stocks
Jan 1, 2027 (e)
47.50 M Stocks
Jan 1, 2028 (e)
47.50 M Stocks

Mediclin Dividend History

8 years of dividend payments

YearAnnual DividendYoY ChangePayments
20250.04EUR↓ 20.0%1×
Jun 5, 20250.04EUR↓ 20.0%1/1
20190.05EUR 0.0%1×
20180.05EUR 0.0%1×
20110.05EUR 0.0%1×
20100.05EUR 0.0%1×
20090.05EUR↓ 50.0%1×
20030.10EUR↓ 33.3%1×
20020.15EUR—1×

Mediclin dividend history and estimates

In 2025, Mediclin paid a dividend amounting to 0.04 EUR. Dividend means that Mediclin distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2010
0.05 EUR
0.00 EUR
Jan 1, 2011
0.05 EUR
0.00 EUR
Jan 1, 2018
0.05 EUR
0.00 EUR
Jan 1, 2019
0.05 EUR
0.00 EUR
Jan 1, 2025
0.04 EUR
0.00 EUR
Jan 1, 2026 (e)
0.00 EUR
0.04 EUR
Jan 1, 2027 (e)
0.00 EUR
0.04 EUR
Jan 1, 2028 (e)
0.00 EUR
0.04 EUR

Mediclin dividend payout ratio

In 2025, Mediclin had a payout ratio of 7.45%. The payout ratio indicates the percentage of the company's profits that Mediclin distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
18.16 %
Jan 1, 2022
15.73 %
Jan 1, 2023
13.78 %
Jan 1, 2024
12.32 %
Jan 1, 2025
7.45 %
Jan 1, 2026 (e)
5.12 %
Jan 1, 2027 (e)
4.79 %
Jan 1, 2028 (e)
4.41 %

Current Mediclin forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
80.00 % (4)
Hold
20.00 % (1)
Sell
0.00 % (0)
12M Price Target
5.87
Last Price
4.30
Currency
EUR
12M Return Potential
36.40 %
LTM Return
0 %

EESG©

Eulerpool ESG Scorecard© for the Mediclin stock

46/100
55
Environment
67
Social
16
Governance
E

Environment

20
Scope 1 - Direct Emissions16,387.37
Scope 2 - Indirect emissions from purchased energy6,550.62
Scope 3 - Indirect emissions within the value chain98,652.38
Total CO₂ emissions22,937.99
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees42.3
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Mediclin shareholder structure

% Name
52.73000%
Asklepios Kliniken Verwaltungsgesellschaft mbH
Asklepios Kliniken Verwaltungsgesellschaft mbH
35.00000%
ERGO Versicherungsgruppe AG
ERGO Versicherungsgruppe AG
0.50921%
Knoesel & Ronge Vermögensverwaltung GmbH & Co. KG
Knoesel & Ronge Vermögensverwaltung GmbH & Co. KG
0.27051%
DFA Australia Ltd.
DFA Australia Ltd.
0.02105%
Baader Bank AG
Baader Bank AG
0.00372%
Mercer Global Investments Management Ltd
Mercer Global Investments Management Ltd

Mediclin Beneficial Ownership Filings (SEC 13D/G)

Free Float
12.3%
Float Shares
-
Shares Outstanding
-

Mediclin Executives and Management Board

20 members · avg. age 54 · 25 % women

Management

JR

Dr. Joachim Ramming (53)

Chairman of the Management Board, Chief Executive Officer

–
TF

Mr. Tino Fritz (49)

Chief Financial Officer, Member of the Management Board

–
TP

Mr. Thomas Piefke (57)

Chief Operating Officer, Member of the Management Board

–
EG

Mr. Ender Gulcan

Head of Investor Relations and Sustainability · since 2024

–

Board of Directors

HH

Mr. Hans Hilpert (59)

Vice Chairman of the Supervisory Board, Employee Representative · since 2002

17,250.00 EUR
DB

Dipl. Kfm. Michael Bock (62)

Independent Member of the Supervisory Board

14,250.00 EUR
MW

Mr. Matthias Werner (51)

Member of the Supervisory Board, Employee Representative

12,743.00 EUR
WE

Ms. Walburga Erichsmeier (63)

Member of the Supervisory Board, Employee Representative · since 2012

12,264.00 EUR
JL

Dr. Jan Liersch (52)

Chairman of the Supervisory Board · since 2019

–
JS

Dr. Julia Dannath Schuh (48)

Independent Member of the Supervisory Board

–

Mediclin Supply Chain

Mediclin Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
1 companies
#NameTrend
1
Muenchener Rueckversicher
Supplier·Customer·Insurance·DE
0.73
0.37
-0.20
-0.07
-0.23
0.09

Frequently asked questions about Mediclin

The business model of Mediclin AG, a leading healthcare provider, revolves around offering a diverse range of medical services and high-quality patient care. With a focus on providing acute care, rehabilitation, and post-acute care, Mediclin AG operates a network of clinics and hospitals across Germany. Its services include specialized medical treatments, innovative therapies, and comprehensive aftercare programs. By constantly striving for medical excellence and employing experienced healthcare professionals, Mediclin AG aims to deliver optimal outcomes for patients. This company's commitment to delivering superior healthcare services has made it a trusted and reliable choice for individuals seeking top-notch medical care in Germany.

Mediclin AG is primarily active in the healthcare industry.

The main competitors of Mediclin AG in the market include big players like Fresenius SE & Co. KGaA, RHÖN-KLINIKUM AG, and Asklepios Kliniken GmbH & Co. KGaA.

Mediclin AG is a renowned healthcare company based in Germany. With a rich history spanning several decades, Mediclin AG has established itself as a leading provider of medical services and rehabilitation facilities. The company focuses on offering high-quality patient care through a network of clinics, acute care hospitals, and outpatient facilities across the country. Mediclin AG is committed to delivering comprehensive healthcare solutions, encompassing various specialties and treatment options. Their dedication to innovation, expertise, and a patient-centered approach has positioned Mediclin AG as a trusted name in the healthcare industry. Continually evolving and adapting to meet the changing needs of the society, Mediclin AG remains dedicated to improving the overall well-being of individuals by delivering exceptional medical care.

Mediclin AG has achieved several significant milestones in its journey. With a strong focus on providing excellent healthcare services, the company has expanded its network and gained recognition in the industry. Mediclin AG has successfully established state-of-the-art medical facilities, attracting renowned doctors and specialists. Through strategic partnerships and acquisitions, Mediclin AG has enhanced its service offerings and geographical presence. The company's commitment to patient care, innovative treatments, and continuous improvement has earned it a reputable position in the healthcare sector. These milestones have propelled Mediclin AG towards further growth and success in delivering high-quality healthcare services to patients.

Mediclin AG is primarily present in Germany.

Mediclin AG represents a set of core values and a corporate philosophy focused on providing high-quality healthcare services. With a strong emphasis on patient-centric care, Mediclin AG aims to prioritize the well-being and satisfaction of patients. The company strives to deliver excellent medical outcomes by continuously investing in cutting-edge technology and medical expertise. Medical professionalism, integrity, and ethical conduct are central to Mediclin AG's approach, ensuring that patients receive reliable and trustworthy healthcare services. By promoting collaboration among medical professionals and fostering a supportive environment, Mediclin AG aims to create a positive and healing experience for all patients.

Analysts currently set an average price target of 5.87 EUR for the Mediclin stock (median: 5.87 EUR), implying +36.4 % versus the latest price. The consensus is based on 5 analyst ratings.

Mediclin Analyst Price Targets 2026

5 analysts currently rate the Mediclin stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Mediclin to generate revenue of 805.60 M EUR and earnings per share of 0.78 EUR.

Mediclin Analyst Price Targets 2026

The Mediclin share (MED.DE) is listed on 7 stock exchanges, including: XETRA (MED.DE), Frankfurt (MED.F), München (MED.MU), Düsseldorf (MED.DU), Hamburg (MED.HM), London (0NDG.L), SIX (Zürich) (MEDCHF.SW).

The Mediclin AG is a company in the healthcare sector that offers various services. The company's headquarters is located in Offenburg and it has clinics, rehabilitation facilities, and nursing homes throughout Germany. The company's divisions include acute hospitals, rehabilitation, post-acute medicine, nursing, and outpatient care. Acute hospitals treat patients with acute illnesses and injuries. The rehabilitation and post-acute medicine departments specialize in helping patients recover after accidents or surgeries. The nursing departments are responsible for caring for older or dependent people. The outpatient services offer various medical services that are provided outside of a hospital setting. Among the products offered by the company are check-up programs in which patients are examined for their health condition. In addition, the company also offers various weight reduction and personal development programs. Additionally, the company offers a variety of therapy services such as physiotherapy, occupational therapy, and speech therapy. The goal of Mediclin AG is to be a holistic healthcare provider that helps people stay healthy and fit on all levels. This means that the company not only offers medical services, but also is active on a psychological and social level. Another business field of the company is research and development. Mediclin AG is involved in various research projects aimed at improving medical care. The company works closely with universities and other research institutes to develop new and innovative methods and technologies. Mediclin AG is a listed company and is listed on the Frankfurt Stock Exchange. The company has a solid financial structure and is able to invest in growth and innovation to increase its competitiveness. Overall, Mediclin AG offers a variety of medical services and products to help people lead healthier lives on many levels. The company follows a comprehensive strategy that ranges from research and development to patient care and is continuously focused on innovation and renewal. Mediclin AG strives to be a reliable and trustworthy partner to its customers in their search for health and well-being.

The expected revenue of Mediclin is 805.60 M EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Mediclin is 37.09 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Mediclin is currently 5.51. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Mediclin stock.

The price-to-sales ratio (P/S) of Mediclin is currently 0.25. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Mediclin stock.

The Eulerpool Quality Score for Mediclin is 3/10.

The ISIN of Mediclin is DE0006595101. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Mediclin is 659510. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Mediclin is MED.DE. The ticker symbol is used to trade Mediclin shares on the stock exchange.

Over the past 12 months, Mediclin paid a dividend of 0.04 EUR . This corresponds to a dividend yield of about 0.93 %. For the coming 12 months, Mediclin is expected to pay a dividend of 0.04 EUR.

The current dividend yield of Mediclin is 0.93 %.

Mediclin pays a dividend, distributed in the months of , , , .

Mediclin paid dividends every year for the past 1 years.

For the upcoming 12 months, dividends amounting to 0.04 EUR are expected. This corresponds to a dividend yield of 0.93 %.

Mediclin is assigned to the 'Health' sector.

To receive the latest dividend of Mediclin from amounting to 0.04 EUR, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

The dividends of Mediclin are distributed in EUR.

All fundamentals and in-depth analysis of Mediclin

Our stock analysis for Mediclin stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mediclin. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Mediclin Stock
Mediclin Revenue→
Mediclin Stock
Mediclin Net Income→
Mediclin Stock
Mediclin P/E→
Mediclin Stock
Mediclin P/S→
Mediclin Stock
Mediclin EBIT→
Mediclin Stock
Mediclin Dividend→
Mediclin Stock
Mediclin Directors Dealings→
Mediclin Stock
Mediclin Stocks→
Mediclin Stock
Mediclin Market capitalization→
Mediclin Stock
Mediclin Debt→
Mediclin Stock
Mediclin Liabilities→
Mediclin Stock
Mediclin Equity→
Mediclin Stock
Mediclin AAQS→
Mediclin Stock
Mediclin Employees→
Mediclin Stock
Mediclin ROE→
Mediclin Stock
Mediclin ROA→
Mediclin Stock
Mediclin ROCE→
Mediclin Stock
Mediclin News→
Mediclin Stock
Mediclin Analyst Price Targets→

Health Stocks

Medico RemediesMediciNovaMedicofarma BiotechMedicine Man TechnologiesMedicon HellasMedicenna TherapeuticsMedicoverMedicare Group QPSCMedicskin HoldingsMedican EnterprisesMedicureMedicamen OrganicsAll Stocks A–Z →